Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Published ·
Keep reading
Loading…